Dexcom, the local maker of continuous glucose monitors, received a warning letter from the Food and Drug Administration last ...

DXCM faces an FDA warning over manufacturing issues, but operations remain unaffected. However, supply-chain risks and rising ...

Dexcom was issued with an FDA warning letter after issues with “manufacturing processes and quality management systems.” ...

Dexcom, a medical device manufacturer that develops continuous glucose monitoring systems, received a warning letter from the FDA regarding manufacturing processes at its facilities in San Diego and ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

DexCom Inc. closed 51.77% below its 52-week high of $142.00, which the company achieved on March 26th.

Investors with a lot of money to spend have taken a bullish stance on DexCom (NASDAQ:DXCM). And retail traders should know. We noticed this today when the positions showed up on publicly available ...

Analysts at William Blair reduced their Q1 2025 earnings estimates for shares of DexCom in a research note issued to ...

Dexcom, the local maker of continuous glucose monitors, received a warning letter from the Food and Drug Administration last week citing issues at two of its manufacturing facilities. The warning ...

Novo Nordisk’s weight loss drug Wegovy is linked to an increased risk of hair loss, a study suggests. Meanwhile, Dexcom ...